A Comparative Phase 1 Study to Evaluate the Pharmacokinetic and Safety of QL2302 vs. Tezspire® in Healthy Subjects

NCT07327697 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

178

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Participants

Interventions

DRUG: QL2302
DRUG: Tezspire

Sponsor

Qilu Pharmaceutical Co., Ltd.